Teva Pharmaceuticals
TEVA
650 hedge funds and large institutions have $19.6B invested in Teva Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 58 funds opening new positions, 240 increasing their positions, 236 reducing their positions, and 88 closing their positions.
5% more capital invested
Capital invested by funds: $18.6B → $19.6B (+$997M)
5% more funds holding in top 10
Funds holding in top 10: 21 → 22 (+1)
1.13% more ownership
Funds ownership: 57.09% → 58.22% (+1.1%)
2% more repeat investments, than reductions
Existing positions increased: 240 | Existing positions reduced: 236
6% less funds holding
Funds holding: 688 → 650 (-38)
34% less first-time investments, than exits
New positions opened: 58 | Existing positions closed: 88
39% less call options, than puts
Call options by funds: $416M | Put options by funds: $681M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$287M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$207M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$207M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$189M |
| 5 |
TIM
Thornburg Investment Management
Santa Fe,
New Mexico
|
+$133M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$155M |
| 2 |
Two Sigma Advisers
New York
|
-$139M |
| 3 |
PC
Paulson & Co
New York
|
-$132M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$108M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$81.6M |
TEVA Hedge Fund Activity: Q2 2017 in Review
650 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q2 2017, worth a combined $19.6B — up 5.4% from $18.6B a quarter earlier.
Sellers outnumbered buyers: 88 funds closed out of TEVA and 58 opened new positions — a net loss of 30 holders — while 236 trimmed existing stakes and 240 added.
The largest buyer was Capital Research Global Investors, adding an estimated $287M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $155M sold.
- 650 institutional investors held Teva Pharmaceuticals (TEVA) as of Q2 2017, down from 688 in Q1 2017.
- Funds reported $19.6B of Teva Pharmaceuticals stock for Q2 2017, up 5.4% quarter-over-quarter.
- 58 funds opened new Teva Pharmaceuticals positions in Q2 2017 and 88 closed out, a net change of -30 holders.
- The largest Teva Pharmaceuticals buyer in Q2 2017 was Capital Research Global Investors, an estimated $287M added.
- The largest Teva Pharmaceuticals seller in Q2 2017 was Renaissance Technologies, an estimated $155M sold.
Based on aggregated 13F filings for Q2 2017.